Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer

[1]  J. Casey.  Colonography and tumor staging during single-session PET/CT , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[2]  Claudio Landoni,et al.  Patients with known or suspected lung cancer: evaluation of clinical management changes due to 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) study , 2005, Nuclear medicine communications.

[3]  S. Holm,et al.  PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  D. Matchar,et al.  FDG-PET for management of cervical and ovarian cancer. , 2005, Gynecologic oncology.

[5]  L. Lapeña,et al.  Impacto de la tomografía por emisión de positrones mediante 18-Fluoro-2-Desoxi-D-Glucosa (PET-FDG) en el manejo terapéutico de pacientes con recurrencia secundaria a cáncer de ovario , 2005 .

[6]  F. Fazio,et al.  Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. , 2004, Radiology.

[7]  B. Hillner,et al.  Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Mortelmans,et al.  Positron Emission Tomography with FDG in the Detection of Peritoneal and Retroperitoneal Metastases of Ovarian Cancer , 2003, Gynecologic and Obstetric Investigation.

[9]  F. Fazio,et al.  Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[10]  O. Hoekstra,et al.  Prospective use of serial questionnaires to evaluate the therapeutic efficacy of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected lung cancer , 2003, Thorax.

[11]  Thomas F Hany,et al.  PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. , 2002, Radiology.

[12]  P. Valk,et al.  The impact of PET on the management of lung cancer: the referring physician's perspective. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  M. Boers,et al.  Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial , 2002, The Lancet.

[14]  E. Yoshikawa,et al.  Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  M. Spieth,et al.  A tabulated summary of the FDG PET literature. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  B. Nowak,et al.  2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. , 2001, Gynecologic oncology.

[17]  S. Reske,et al.  FDG-PET for clinical use , 2001, European Journal of Nuclear Medicine.

[18]  F. Abdul-Karim,et al.  Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. , 2001, Gynecologic oncology.

[19]  K. Togashi,et al.  Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. , 2001, AJR. American journal of roentgenology.

[20]  E. Pauwels,et al.  Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology , 2001, Journal of Cancer Research and Clinical Oncology.

[21]  P. Valk,et al.  Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  Paul Kinahan,et al.  A combined PET/CT scanner for clinical oncology. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[24]  S S Gambhir,et al.  A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  B J McNeil,et al.  Staging of advanced ovarian cancer: comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group. , 2000, Radiology.

[26]  B. McNeil,et al.  Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis--report of the Radiology Diagnostic Oncology Group. , 1999, Radiology.

[27]  Gary T. Smith,et al.  Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[28]  R. Delgado-Bolton,et al.  [Impact of positron emission tomography with FDG-PET in treatment of patients with suspected recurrent ovarian cancer]. , 2005, Revista espanola de medicina nuclear.

[29]  W. Kuschner,et al.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.

[30]  A. Hogg,et al.  High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[31]  V Kalff,et al.  Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Sandler,et al.  Turnaround: Time to Take a Look , 2001 .

[33]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[34]  F. Tas,et al.  Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer. , 2000, European journal of gynaecological oncology.

[35]  G. V. von Schulthess,et al.  Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma , 2000, European Radiology.